ct-388 peptide CT-388 is a once-weekly subcutaneous dual glucagon-like peptide 1 (GLP-1 - CT-388structure CT-388 administered once-weekly resulted in clinically meaningful weight loss CT-388: A Promising Dual GLP-1/GIP Agonist for Obesity and Type 2 Diabetes

CT-388Phase 2 The investigational peptide CT-388 is emerging as a significant contender in the development of novel treatments for obesity and type 2 diabetes.The petrelintide/CT-388FDC will target the specific segments of people with overweight and obesity who need additional benefits beyond amylin monotherapy, ... As a once-weekly subcutaneous injectable, CT-388 acts as a dual agonist, targeting both GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide) receptors. This dual-action mechanism aims to enhance its efficacy in promoting weight loss and improving glycemic control, offering a new avenue for patients struggling with these chronic conditions. Early clinical trial data has shown promising results, positioning CT-388 as a potentially valuable addition to the growing landscape of incretin-based therapies.

Understanding CT-388's Mechanism of Action

CT-388's therapeutic potential lies in its ability to selectively activate both GLP-1 and GIP receptors75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP .... GLP-1 receptor agonists are well-established for their roles in stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite, all of which contribute to weight loss and improved blood sugar management.Roche's Obesity Drug Shows 22.5% Weight Loss in Phase ... GIP, another incretin hormone, also plays a role in glucose homeostasis and has been shown to complement the effects of GLP-1, particularly in managing metabolic dysfunction. By simultaneously engaging both receptor pathways, CT-388 is designed to offer a more comprehensive and potent metabolic benefit compared to single-receptor agonists. This dual agonism is believed to be key to its observed efficacy in suppressing appetite, reducing body weight, and improving metabolic dysfunction-associated steatohepatitis in preclinical studies.

Clinical Development and Trial Results

Roche, through its subsidiary Genentech, is advancing the development of CT-388, with the drug progressing through various phases of clinical trials.CT 388 is a subcutaneously administered peptidethat acts as a dual agonist of the gastric inhibitory polypeptide receptor (GIP) and ... Early studies, including Phase Ib and Phase II trials, have provided encouraging topline resultsInvestigational Dual GLP-1/GIP Agonist CT-388 .... For instance, a Phase II trial demonstrated that a 24mg dose of CT-388 led to significant weight loss, with a notable percentage of participants achieving resolution of obesity. In one study, participants lost up to 22.作者：M CHAKRAVARTHY·2023·被引用次数：10—75-LB:CT-388, a Novel Once-Weekly Dual GLP-1 and GIP Receptor Modulator, Is Safe, Well-Tolerated, and Produces More than 8% Weight Loss in Four ...5% of their body weight at 48 weeks. Furthermore, CT-388 has shown positive effects on glycemic control, with some trials indicating a normalization of blood sugar levels in participants with type 2 diabetes. The drug has generally been found to be safe and well-tolerated, with adverse events consistent with its drug class. These findings have supported the decision to advance CT-388 into Phase 3 testing, a crucial step towards potential regulatory approval.

CT-388 in the Context of Obesity and Diabetes Treatment

The development of CT-388 comes at a time when the demand for effective obesity and type 2 diabetes treatments is at an all-time high3天前—Roche said that when it came to the treatment-regimen estimand, the placebo-adjusted weight loss achieved withCT-388was 18.3%. The company .... Existing therapies, such as GLP-1 receptor agonists like semaglutide and tirzepatide (which also targets GIP), have revolutionized the management of these conditions. CT-388 aims to build upon this progress by offering a potentially differentiated profile.Roche GLP-1 produces “robust” weight loss in phase II ... While it targets similar pathways to existing blockbusters, its specific signaling bias and dual-receptor activation may offer unique advantages or cater to patient segments who may not respond optimally to monotherapy. The drug's once-weekly subcutaneous administration also offers convenience for patients作者：MV Chakravarthy·2025—CT-388 is being developed as a once-weekly injectable therapy for obesity and type 2 diabetes. Abstract. Biased agonism of the glucagon-like peptide-1/glucose- .... As CT-388 moves closer to potential market entry, it represents a significant area of interest for healthcare providers, researchers, and individuals seeking advanced therapeutic options for metabolic health75-LB: CT-388, a Novel Once-Weekly Dual GLP-1 and GIP ....

Future Outlook and Considerations

The journey of CT-388 from investigational compound to approved medication involves rigorous clinical evaluation and regulatory reviewPetrelintide / CT-388 - Pipeline - Zealand Pharma. The successful completion of Phase 3 trials will be critical in confirming its long-term efficacy, safety, and comparative advantages. While the data thus far is promising, ongoing research will further elucidate its precise role in the treatment armamentarium for obesity and type 2 diabetes. The competitive landscape is dynamic, with other dual GLP-1/GIP agonists and novel mechanisms of action also in development. However, CT-388's demonstrated potential for substantial weight loss and improved glycemic control positions it as a strong candidate to address unmet needs in metabolic disease management.